Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KIF18A | Q8NI77 | 15/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29578579 | 1.00 | MEN1 (0.40) | MEN1KMT2ACYP3A4MAPK1CYP2C19 | |
| SCHEMBL27357674 | 0.89 | NPC1 (0.39) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL31463589 | 0.85 | KIF18A (0.53) | KIF18A | |
| SCHEMBL26151048 | 0.85 | FFAR4 (0.48) | MEN1KMT2ACYP3A4MAPK1CYP2C19 | |
| SCHEMBL25712739 | 0.85 | KIF18A (0.41) | KIF18AUSP2 | |
| SCHEMBL22119473 | 0.84 | KIF18A (0.41) | MEN1KMT2ACYP3A4MAPK1CYP2C19 | |
| SCHEMBL22119526 | 0.83 | KIF18A (0.38) | KIF18AUSP2 | |
| SCHEMBL26646192 | 0.82 | KIF18A (0.37) | KIF18A | |
| SCHEMBL30748599 | 0.82 | CDC7 (0.44) | MEN1KMT2ACYP3A4KIF18AKDM4E | |
| SCHEMBL27354156 | 0.82 | NPC1 (0.44) | MEN1KMT2ACYP3A4MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023088441-A1 | KIF18A INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2021026098-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | KIF18A, KIF18B, KIF20A | MEN1 1697/4885KMT2A 326/4885CYP3A4 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.